Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Aafke Creemers
Observed names:
A. Creemers,
Creemers, A.,
Creemers, Aafke
Institution:
Amsterdam UMC Location University of Amsterdam
Observed institutions:
Amsterdam UMC Location University of Amsterdam,
Amsterdam University Medical Centers,
Cancer Center Amsterdam,
University of Amsterdam
ORCID:
0000-0002-7082-8183
Observed ORCID:
0000-0002-7082-8183
OpenAlex ID:
A5019863663
Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma
2019
·
Eva A. Ebbing
, Amber P. van der Zalm
, et al.
·
Proceedings of the National Academy of Sciences
·
197
Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma
2019
·
Marin Strijker
, Eline C. Soer
, et al.
·
International Journal of Cancer
·
118
PDF
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study
2019
·
Charlotte I. Stroes
, Sandor Schokker
, et al.
·
Journal of Clinical Oncology
·
76
PDF
Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis
2017
·
A. Creemers
, S. Krausz
, et al.
·
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
·
73
Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis
2023
·
Norbert Moldovan
, Ymke van der Pol
, et al.
·
Cell Reports Medicine
·
70
A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas
2018
·
Aafke Creemers
, Eva A. Ebbing
, et al.
·
Scientific Reports
·
39
PDF
Chemoradiation induces epithelial‐to‐mesenchymal transition in esophageal adenocarcinoma
2019
·
Anne Steins
, Eva A. Ebbing
, et al.
·
International Journal of Cancer
·
38
PDF
Comparing cytotoxic backbones for first‐line trastuzumab‐containing regimens in human epidermal growth factor receptor 2‐positive advanced oesophagogastric cancer: A meta‐analysis
2018
·
Emil ter Veer
, Aafke Creemers
, et al.
·
International Journal of Cancer
·
38
PDF
Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer
2022
·
Merel J. M. van Velzen
, Aafke Creemers
, et al.
·
Gastric Cancer
·
32
PDF
Tumor‐immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas
2021
·
Tanya TD Soeratram
, Aafke Creemers
, et al.
·
The Journal of Pathology
·
29
The dynamics of HER2 status in esophageal adenocarcinoma
2018
·
Aafke Creemers
, Eva A. Ebbing
, et al.
·
Oncotarget
·
26
PDF
Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis
2017
·
A. Creemers
, E. ter Veer
, et al.
·
Scientific Reports
·
25
PDF
Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis
2018
·
Emil ter Veer
, Tom van den Ende
, et al.
·
Acta Oncologica
·
19
PDF
Genome-wide cell-free DNA termini in patients with cancer
2021
·
Norbert Moldovan
, Ymke van der Pol
, et al.
·
medRxiv
·
12
PDF
The pluripotency factor NANOG contributes to mesenchymal plasticity and is predictive for outcome in esophageal adenocarcinoma
2024
·
Amber P. van der Zalm
, Mark P. G. Dings
, et al.
·
Communications Medicine
·
11
Genome‐wide and panel‐based cell‐free DNA characterization of patients with resectable esophageal adenocarcinoma
2023
·
Tom van den Ende
, Ymke van der Pol
, et al.
·
The Journal of Pathology
·
11
PDF
Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
2019
·
Sandor Schokker
, Stephanie O. van der Woude
, et al.
·
Cancers
·
8
PDF
FOXO transcriptional activity is associated with response to chemoradiation in EAC
2022
·
A. Creemers
, A. P. van der Zalm
, et al.
·
Journal of Translational Medicine
·
4
PDF
Correction for Ebbing et al., Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma
2021
·
Ebbing, Eva A.
, van der Zalm, Amber P.
, et al.
·
Proceedings of the National Academy of Sciences
·
3
Signal transduction pathway activity during neoadjuvant treatment in esophageal adenocarcinomas
2018
·
A. Creemers
, S.L. Meijer
, et al.
·
Annals of Oncology
·
2
Comparison of cytotoxic backbones for first line trastuzumab-containing regimens in HER2-positive advanced esophagogastric cancer: A meta-analysis
2017
·
E. ter Veer
, A. Creemers
, et al.
·
Annals of Oncology
·
1
PDF
Biomarkers in gastro-esophageal cancer:From bedside to bench and back
2024
·
Creemers, A.
·
UvA-DARE (University of Amsterdam)
Circulating tumor DNA (ctDNA) analysis by low-coverage whole genome sequencing (lcWGS) of resectable esophageal adenocarcinoma (rEAC) patients.
2021
·
Tom van den Ende
, Aafke Creemers
, et al.
·
Journal of Clinical Oncology
Exploring candidate signal transduction pathways for targeted therapy in esophageal cancer
2019
·
A. Creemers
, S.L. Meijer
, et al.
·
Annals of Oncology
Trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy in resectable HER2+ esophageal adenocarcinoma patients: An update on survival and predictive biomarkers in the TRAP study
2019
·
C.I. Stroes
, A. Creemers
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
35
Citation count:
832
H-index:
13
I10-index:
16
Year
Topic
Type